<DOC>
	<DOC>NCT01235507</DOC>
	<brief_summary>This open-label, single arm study will assess the safety and efficacy of RoActem ra/Actemra (tocilizumab) in combination with methotrexate in patients with activ e moderate to severe rheumatoid arthritis who have an inadequate response to dis ease-modifying antirheumatic drugs (DMARDs). Patients will receive RoActemra/Act emra at a dose of 8 mg/kg (maximum 800 mg) intravenously every 4 weeks for a tot al of 6 infusions. Methotrexate will be continued at a stable dose. Anticipated time on study treatment is 24 weeks.</brief_summary>
	<brief_title>A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Active moderate to severe rheumatoid arthritis (RA) On methotrexate treatment (oral or parenteral) for at least 12 weeks, at stable dose of at least 15 mg/week for at least 6 weeks Oral corticosteroids must have been at stable dose of &lt;/= 10 mg/day prednisone (or equivalent) for at least 25 out of 28 days prior to first dose of study drug Body weight &lt;/= 150 kg Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months of study entry Rheumatic autoimmune disease other than RA Functional class IV according to American College of Rheumatology (ACR) classification Prior history of or current inflammatory joint disease other then RA Treatment with traditional DMARDs other than methotrexate within 1 month (for leflunomide 3 months) prior to baseline Treatment with any biologic drug that is used in the treatment or RA Intraarticular or parenteral corticosteroids within 6 weeks prior to baseline Known active current or history of recurrent infection History of or currently active primary or secondary immunodeficiency Positive for HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>